| Title: |
Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey. A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC |
| Authors: |
Christodorescu, Ruxandra; Geavlete, Oliviana; Ferrini, Marc; Kümler, Thomas; Toutoutzas, Konstantinos; Bayes-Genis, Antoni; Seferovic, Petar; Metra, Marco; Chioncel, Ovidiu; Rosano, Giuseppe M C; Savarese, Gianluigi |
| Contributors: |
Christodorescu, Ruxandra; Geavlete, Oliviana; Ferrini, Marc; Kümler, Thoma; Toutoutzas, Konstantino; Bayes-Genis, Antoni; Seferovic, Petar; Metra, Marco; Chioncel, Ovidiu; Rosano, Giuseppe M C; Savarese, Gianluigi |
| Publisher Information: |
John Wiley and Sons Ltd |
| Publication Year: |
2025 |
| Subject Terms: |
Guideline-directed medical therapy; Heart failure with reduced ejection fraction; Implementation; Sodium–glucose cotransporter 2 inhibitor |
| Description: |
Aims: Real-world data show that guidelines are insufficiently implemented, and particularly guideline-directed medical therapies (GDMT) are underused in patients with heart failure and reduced ejection fraction (HFrEF) in clinical practice. The Council for Cardiology Practice and the Heart Failure Association of the European Society of Cardiology (ESC) developed a survey aiming to (i) evaluate the perspectives of the cardiology community on the 2021 ESC heart failure (HF) guidelines, (ii) pinpoint disparities in disease management, and (iii) propose strategies to enhance adherence to HF guidelines. Methods and results: A 22-question survey regarding the diagnosis and treatment of HFrEF was delivered between March and June 2022. Of 457 physicians, 54% were general cardiologists, 19.4% were HF specialists, 18.9% other cardiac specialists, and 7.7% non-cardiac specialists. For diagnosis, 52.1% employed echocardiography and natriuretic peptides (NPs), 33.2% primarily used echocardiography, and 14.7% predominantly relied on NPs. The first drug class initiated in HFrEF was angiotensin-converting enzyme inhibitors/angiotensin receptor-neprilysin inhibitor (ACEi/ARNi) (91.2%), beta-blockers (BB) (73.8%), mineralocorticoid receptor antagonists (MRAs) (53.4%), and sodium-glucose cotransporter 2 (SGLT2) inhibitors (48.1%). The combination ACEi/ARNi + MRA+ BB was preferred by 39.3% of physicians, ACEi/ARNi + SGLT2 inhibitors + BB by 33.3%, and ACEi/ARNi + BB by 22.2%. The time required to initiate and optimize GDMT was estimated to be 6 months by 7.9%. Compared to general cardiologists, HF specialists/academic cardiologists reported lower estimated time-to-initiation, and more commonly preferred a parallel initiation of GDMT rather than a sequential approach. Conclusion: Participants generally followed diagnostic and treatment guidelines, but variations in HFrEF management across care settings or HF specialties were noted. The survey may raise awareness ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/39318024; info:eu-repo/semantics/altIdentifier/wos/WOS:001322455800001; volume:27; issue:3; firstpage:412; lastpage:420; journal:EUROPEAN JOURNAL OF HEART FAILURE; https://hdl.handle.net/20.500.11768/193813 |
| DOI: |
10.1002/ejhf.3444 |
| Availability: |
https://hdl.handle.net/20.500.11768/193813; https://doi.org/10.1002/ejhf.3444 |
| Accession Number: |
edsbas.AA0EE0ED |
| Database: |
BASE |